ArticleBlood advances2022
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.Blood advances · 2026Trial
- IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.Haematologica · 2024Trial
- Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma.Haematologica · 2026Article
- Ivermectin Treatment forCase reports in hematology · 2026Article
- SOHO State of the Art Updates and Next Questions | Current and Emerging Novel Treatments for Marginal Zone Lymphoma.Clinical lymphoma, myeloma & leukemia · 2026Review
- Non-gastric mucosa-associated lymphoid tissue lymphomas: a narrative review of pathogenesis, diagnosis, and treatment strategies.Annals of translational medicine · 2025Review
- Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract.Cancer management and research · 2025Article
- Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia.Hematological oncology · 2024Review
- Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study.Hematological oncology · 2024Article
- Delphi consensus recommendations on treatment for advanced-stage marginal zone lymphoma in South Korea.Annals of hematology · 2024Article
- More is not always better, sometimes it is just more.Haematologica · 2024Article
- Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.Oncology research · 2024Article
- Advances in the treatment of relapsed/refractory marginal zone lymphoma.Frontiers in oncology · 2024Review
- Characteristics, efficacy, and prognosis analysis of newly diagnosed marginal zone lymphoma.Frontiers in immunology · 2024Article
- Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.Journal of hematology & oncology · 2023Article
- Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.Expert review of hematology · 2023Review
- Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.Journal of clinical medicine · 2022Review
- Management of marginal zone lymphomas.Hematology. American Society of Hematology. Education Program · 2022Article
- A roadmap for clinical trial design in marginal zone lymphoma.American journal of hematology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 20 institutions in 2 countries.
Funding
Abstract
Extranodal marginal zone lymphoma (EMZL) is a heterogeneous non-Hodgkin lymphoma. No consensus exists regarding the standard-of-care in patients with advanced-stage disease. Current recommendations are largely adapted from follicular lymphoma, for which bendamustine with rituximab (BR) is an established approach. We analyzed the safety and efficacy of frontline BR in EMZL using a large international consortium. We included 237 patients with a median age of 63 years (range, 21-85). Most patients presented with Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 (n = 228; 96.2%), stage III/IV (n = 179; 75.5%), and intermediate (49.8%) or high (33.3%) Mucosa Associated Lymphoid Tissue International Prognosis Index (MALT-IPI). Patients received a median of 6 (range, 1-8) cycles of BR, and 20.3% (n = 48) received rituximab maintenance. Thirteen percent experienced infectious complications during BR therapy; herpes zoster (4%) was the most common. Overall response rate was 93.2% with 81% complete responses. Estimated 5-year progression-free survival (PFS) and overall survival (OS) were 80.5% (95% CI, 73.1% to 86%) and 89.6% (95% CI, 83.1% to 93.6%), respectively. MALT-IPI failed to predict outcomes. In the multivariable model, the presence of B symptoms was associated with shorter PFS. Rituximab maintenance was associated with longer PFS (hazard ratio = 0.16; 95% CI, 0.04-0.71; P = .016) but did not impact OS. BR is a highly effective upfront regimen in EMZL, providing durable remissions and overcoming known adverse prognosis factors. This regimen is associated with occurrence of herpes zoster; thus, prophylactic treatment may be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.